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Abstract
Background: It has been shown that single nucleotide polymorphisms (SNPs) near the interleukin 
28B (IL28B) gene were associated with sustained viral response following standard treatment of 
hepatitis C virus infection. 
Aim: The aim of the study was to evaluate the association between the SNPs near the IL28B 
gene and the response to the treatment of chronic hepatitis C. 
Methods: The genotyping of the three IL28B gene polymorphisms: rs12979860, rs8099917, 
and rs12980275 was done in 100 Caucasian patients with chronic hepatitis C previously treated with 
standard antiviral therapy. The study group consisted of 28 hemodialysis patients with end stage 
renal disease treated with pegylated interferon α and 72 patients without renal disease treated with 
pegylated interferon α and ribavirin. All patients finished the antiviral treatment at least 6 months before 
enrollment in the study. Sustained viral response, defined as an absence of detectable HCV RNA in 
the serum, was tested by an assay with a sensitivity of 20 IU/mL.
Results: Sustained viral response was achieved in 56% (56/100) of the treated patients. The 
three IL28B gene polymorphisms (CC genotype of rs12979860, TT genotype of rs8099917, and AA 
genotype of rs12980275) were associated with sustained viral response (p=0.006, p=0.002, p=0.007, 
respectively) in study patients with chronic hepatitis C treated with standard antiviral therapy. 
Conclusion: The IL28B gene polymorphisms: rs12979860, rs8099917, and rs12980275 were 
significantly associated with the successful treatment of chronic hepatitis C. 
A novel family of antiviral cytokines was described and designated 
as type III interferons. The interferon type III family consists of 
three cytokines: Interleukin 29 (interferon lambda 1, IFNλ1), 
Interleukin 28A (interferon lambda 2, IFNλ2), and Interleukin 28B 
(interferon lambda 3, IFNλ3). IFNλ is rapidly induced during HCV 
infection and has antiviral activity against the virus. The type III 
interferons induce antiviral activity through both innate and adaptive 
immune pathways [7-9].
The IL28B gene encodes the cytokine interferon lambda 3, IFNλ3. 
Four genome wide association studies (GWAS) had associated 
treatment-induced clearance of HCV following PEGIFN/RBV therapy 
with the single nucleotide polymorphisms (SNPs) near the interleukin 
28B (IL28B) gene on chromosome 19 [10-13]. Differences in genetic 
sequences among individuals are called genetic polymorphisms. The 
GWAS showed that SNPs near the IL28B gene (CC of rs12979860, 
TT of rs8099917, and AA of rs12980275) were significantly associated 
with the successful treatment of chronic hepatitis C. The chance of 
cure with this standard treatment is twice as high in patients who 
are homozygous for cytosine in this location (the CC genotype) than 
in those who are heterozygous (CT) or homozygous for thymine 
in this location (the TT genotype). The mechanism underlying the 
association between the IL28B gene polymorphism and response to 
hepatitis C treatment is not well understood.
Introduction
Hepatitis C virus (HCV) has often been referred to as the “silent 
virus,” as most HCV infections are clinically silent until the disease 
reaches a late stage, which often occurs several decades after initial 
infection. Although a variety of host factors play a role in eradication 
of HCV, only 15%-25% of adults spontaneously clear the infection 
[1]. The remaining 75%-85% of patients continue to have persistent 
viremia, life-long HCV infection, chronic hepatitis C [2]. 
In the early 2000s, the combination of pegylated interferon alpha 
(PEGIFNα) and daily doses of ribavirin (RBV) became the standard-
of-care (SOC) treatment for chronic hepatitis C [3,4]. The primary 
goal of the treatment is eradication of HCV, which is synonymous 
with sustained viral response (SVR), defined as undetectable HCV 
RNA in blood, 24 weeks after completion of the antiviral treatment 
[5]. The PEGIFN/RBV treatment is prolonged and expensive, 
complicated by side effects leading to treatment discontinuation, 
and only about one-half of the treated patients infected with HCV 
genotype 1 are achieving sustained viral response [6].
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The aim of the study was to evaluate the association between single 
nucleotide polymorphisms near the IL28B gene and the response to 
the treatment of chronic hepatitis C. 
Patients and Methods
Patients
A study group of 100 adult Caucasian patients with chronic 
hepatitis C rou tinely treated with antiviral therapy was investigated in 
the study. The study was approved by the local Ethics Committee and 
written informed consent was obtained from each study participant. 
The cohort consisted of 28 patients with end stage renal disease on 
hemodialysis (HD) treatment and 72 patients without renal disease 
(non-renal). The HD patients received antiviral therapy only with 
pegylated interferon α-2a (PEGIFNα-2a). The non-renal patients were 
treated with pegylated interferon α-2a or α-2b (PEGIFNα-2b) plus 
ribavirin. The pegylated interferon was administered subcutaneously 
once a week in a standard dose (PEGIFNα-2a: 135 μg for HD patients 
and 180 μg for non-renal patients, and PEGIFNα-2b:1.5µg/kg). The 
ribavirin was administered daily in a dose of 1000 mg for patients 
with body weight less than 75 kg and 1200 mg for patients with body 
weight over than 75 kg when was combined with PEG IFNα-2a. The 
ribavirin dose was 800 mg for patients with body weight less than 65 
kg, 1000 mg for patients with body weight 65–85 kg and 1200 mg 
for patients with body weight over than 85 kg when was combined 
with PEG IFNα-2b. The treatment duration was 24 weeks for patients 
infected with HCV genotype 2 and 3, and 48 weeks for the infection 
caused by HCV genotype 1 and 4. All patients finished the antiviral 
treatment at least 6 months before enrollment in the study. Sustained 
viral response (SVR), defined as an absence of detectable HCV RNA 
in the serum, 6 months after completion of the antiviral treatment, 
was tested by an assay with a sensitivity of 20 IU/mL.
Methods
Peripheral blood samples in EDTA as an anticoagulant were 
obtained from each patient enrolled in the study. 
HCV quantification
Hepatitis C virus RNA was extracted from plasma using 
QIAamp Viral RNA kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. Reverse transcriptase- polymerase chain 
reaction (RT-PCR) assay for HCV quantification was done with HCV 
Real-TM Quant (Sacace Biotechnologies, Como, Italy) on Stratagene 
MX3005P real-time PCR system (Agilent Technologies, Edinburgh, 
UK) according to manufacturer’s instructions. Detection limit of the 
assay is 20 IU/ml. 
IL28B polymorphisms genotyping
Peripheral blood mononuclear cells (PBMCs) were isolated by 
density-gradient centrifugation using Histopaque-1077 (Sigma-
Aldrich,  Munich, Germany) and homogenized in Tri Reagent 
Solution (Ambion, Life Technologies and Carlsbad, CA, USA). 
Genomic DNA was extracted from PBMCs homogenized in Tri 
Reagent Solution (Ambion, Life Technologies, Carlsbad, CA, USA) 
according to manufacturer’s instructions and genotyped for three 
IL28B polymorphisms: rs8099917, rs12979860 and rs12980275. The 
rs8099917 polymorphism was genotyped using TaqMan predesigned 
SNP genotyping assay (reference C_11710096_10, Applied 
Biosystems) according manufacturer’s recommended protocol in a 
total volume of 25µl. The two later SNPs were genotyped using custom 
designed TaqMan assays with the following primes and probes: 
TCTACTGAACCAGGGAGCTC, GCGCGGAGTGCAATTCAAC, 
6Fam-TGGTTCACGCCTTC, Vic-TGGTTCGCGCCTTC 
for rs12979860, and GTGCTGAGAGAAGTCAAATTCC, 
CCGCTACCCGGCAAATATT, 6Fam-ACACGTCCGTTTCTA, 
Vic-AGACACGTCTGTTTCTA for rs12980275 [14]. For both assays 
20ng of DNA was used in a total volume of 25µl including 12,5µl 
TaqMan Universal PCR master Mix (2x), 1µM of each primer and 
200nM of each probe. The PCR reaction conditions were as follows: 
initial denaturing at 95°C for 10min; 40 cycles of 15 sec at 92°C and 1 
min at 64°C to reduce miss priming. Thermal cycling was performed 
using a Stratagene MX3005P real-time PCR system (Agilent 
Technologies, Edinburgh, UK). Both positive and negative controls 
were included in every genotyping assay. 
Statistical analysis
Statistical analysis of data was performed using SPSS Statistics 
17.0. The parametric variables are presented as the mean and standard 
deviation. A logistic regression model was used to determine the 
predictors of the SVR. Odds ratios (ORs) and 95% confidence 
intervals (95% CIs) were derived from the logistic regression model. 
The Fisher’s exact test was used to compare proportions. A p value 
was calculated with two tails. A two-tailed p value of less than or equal 
to 0.05 was considered statistically significant.
Results
The study group included 100 patients, 71 (71%) men and 29 
(29%) women, with a mean age of 43.5 ± 11.4 years. All patients 
were Caucasians. The HCV genotype 1 caused the chronic hepatitis 
C infection in most of the patients (93%, 93/100 patients). The HCV 
genotype 2 and 4 were present in two patients respectively and HCV 
genotype 3 in one patient. Dual infection with genotype 1 and 3 was 
also identified in two patients. Sustained viral response was achieved 
in 56% (56/100) of the treated patients, confirmed by RT-PCR assay 
with detection limit of 20 IU/ml (Table 1). 
The distribution of the frequencies of rs12979860 genotypes in 
the study group was as follows: 36 (36%) patients with CC genotype, 
Table 1: The demographic features, distribution of HCV genotypes and the 
treatment response rate in all study participants.
 Patients, Number 100
 Gender, Number (%) 
 Man 71 (71.0%)
 Womenv 29 (29.0%)
 Age, year, mean ± SD 43.5 ± 11.4
 HCV genotype, Number (%)
 G1 93 (93.0%)
 G2 2 (2.0%)
 G3 1 (1.0%)
 G4 2 (2.0%)
 G1 + G3 2 (2.0%)
 Sustained viral response rate, Number (%) 56 (56.0%)
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51 (51%) patients with CT genotype, and 13 (13%) patients with TT 
genotype (Figure 1). The distribution of the frequencies of rs8099917 
genotypes was: 59 (59%) patients with TT genotype, 32 (32%) patients 
with TG genotype, and 9 (9%) patients with GG genotype (Figure 
2). The distribution of the frequencies of rs12980275 genotypes was: 
38 (38%) patients with AA genotype, 50 (50%) patients with AG 
genotype, and 12 (12%) patients with GG genotype (Figure 3).
The genotype distributions for rs12979860 (CC vs. CT and TT), 
rs8099917 (TT vs. TG and GG), and rs12980275 (AA vs. AG and GG) 
polymor phisms were significantly different between SVR group and 
non SVR group. The achievement of sustained viral response was 
significantly higher in patients with CC genotype of rs1297860 than in 
the patients with non CC genotypes (75% vs. 45.3%, p=0.006), Table 
2. The SVR was achieved in 75% of patients with the genotype CC of 
rs12979860, compared with 45.3% of patients with the genotype CT 
or TT. The occurrence of SVR was significantly higher in patients with 
TT genotype of rs8099917 than in patients with non TT genotypes 
(69.5% vs. 36.6%, p=0.002), Table 2. There was also significant 
association between SVR and rs12980275, SVR was achieved in 73.7% 
of patients with AA genotype versus 45.2% of patients with non AA 
genotypes (p=0.007), Table 2. 
Gender (OR 1.17, 95% CI, 0.94-1.45, p=0.153), age (OR 0.99, 95% 
CI, 0.98-1.00, p=0.098), and HCV genotype (OR 1.46, 95% CI, 0.94-
2.28, p=0.098) were not significantly associ ated with achievement of 
the SVR.
Discussion
The three most widely studied SNPs near the IL28B gene in the 
genome wide association studies [10-13], were also identified in our study, to evaluate their association with the treatment-induced 
clearance of HCV in the patients treated with PEGIFN/RBV. The 
genome wide association studies identified that the homozygosis 
for the C allele of rs12979860, the homozygosis for the T allele of 
rs8099917, and the homozygosis for the A allele of rs12980275 
were favorable genotypes which predicted treatment response. The 
same favorable genotypes were associated with the achievement of 
sustained viral response in treated patients in our study. Most of 
the studies investigated the effect of the IL28B gene polymorphisms 
on the SVR in patients with HCV genotype 1. Almost all of treated 
patients in our study were infected with HCV genotype 1, only 7% 
of the patients were infected with genotypes 2, 3 and 4. The study 
of Eslam M et al. [15], confirmed similar effects of the IL28B gene 
polymorphisms on the SVR in Caucasian patients infected with HCV 
genotypes 2, 3 and 4 as in the patients with HCV genotype 1. 
The distribution of frequencies of rs12979860 genotypes in 
our study group was: CC in 36%, CT in 51% and TT in 13% of the 
participants. In Latvia, majority of the people are Caucasians, and 
they reported similar distribution of frequencies of rs12979860: CC 
in 33%, CT in 53% and TT in 14% of study participants (Caucasians, 
n=142) [16]. Similar to our findings, the distribution of frequencies of 
rs8099917 genotypes among study participants (Caucasians, n= 175) 
in the study of Sticchi L et al., was as follows: TT in 55%, TG in 40% 
and GG in 5% [17].
The achieved SVR in the study was 56% and it was associated with 
36 51 13
0 20 40 60 80 100
rs12979860
CC CT TT
Figure 1: Distribution of the frequencies of rs12979860 genotypes in study 
participants.
59 32 9
0 20 40 60 80 100
rs8099917
TT TG GG
Figure 2: Distribution of the frequencies of rs8099917 genotypes in study 
participants.
38 50 12
0 20 40 60 80 100
rs12980275
AA AG GG
Figure 3: Distribution of the frequencies of rs12980275 genotypes in study 
participants.
Table 2: Association between the sustained viral response and the IL28B gene 
polymorphisms.
rs12979860 CC† non CC (CT,TT) †† Total p
SVRa, No (%) 27 (75%) 29 (45.3%)  56
Non SVRb, No (%) 9.0 (25%) 35 (54.7%)  44 0.006
Total 36 (100%) 64 (100%) 100
rs8099917 TT† non TT (TG,GG) †† Total p
SVRa, No (%) 41 (69.5%) 15 (36.6%)  56
Non SVRb, No (%) 18 (30.5%) 26 (63.4%)  44 0.002
Total 59 (100%) 41 (100%) 100
rs12980275 AA† non AA (AG,GG) †† Total p
SVRa, No (%) 28 (73.7%) 28 (45.2%)  56
Non SVRb, No (%) 10 (26.3%) 34 (54.8%)  44 0.007
Total 38 (100%) 62 (100%) 100
aAchieved sustained viral response; bNo achievement of sustained viral 
response; † Favorable genotype of IL28B gene polymorphisms; †† Not favorable 
genotypes of IL28B gene polymorphisms.
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the favorable genotypes of the IL28B gene polymorphisms. Consistent 
to our findings were the results from the study of Domagalski K et al. 
[18]. The predictability of the three most widely studied SNPs on the 
treatment response was determined in the cohort of 174 Caucasian 
(Polish) patients infected with HCV genotype 1 and 4 treated with 
PEGIFN/RBV. The CC genotype of rs12979860, TT genotype of 
rs8099917, and AA genotype of rs12980275 were significantly 
associated with the successful treatment (p=0.001, p=0.016, and 
p=0.002, respectively) [18]. Similar SVR rates and association with 
the IL28B gene polymorphisms were evaluated in the studies of 
Sporea I et al. [19] and Tolmane I et al. [16], although they studied 
only the rs12979860 as SNP. The study of Sporea I et al. included a 
cohort of 107 Caucasian (Romanian) patients infected with HCV 
genotype 1 treated with PEGIFN/RBV [19]. The SVR rate was 50.5% 
and there was a significant association between the SVR and CC 
genotype of rs12979860 (73.1% in the CC genotype vs. 43.7% in the 
non CC genotypes, p=0.012). The study of Tolmane I et al. included 
142 Caucasian (Latvian) patients infected with HCV genotype 1 
(61%) and HCV genotype 2 or 3 (39%) treated with PEGIFN/RBV 
[16]. The SVR rate was 59%, and it was significantly associated with 
the CC genotype of rs12979860 (74% in the CC genotype vs. 52% in 
the non CC genotypes, p=0.002). 
Conclusions
The IL28B gene polymorphisms are strong predictors of the 
responsiveness to interferon-based regimen, and their determination 
has demonstrated a great potential to improve patient care. To date, 
direct antiviral agents including first and second generation protease 
inhibitors and the polymerase inhibitors represent the available 
options for highly effective interferon containing and interferon-
free regiments for HCV eradication. In near future, even more 
direct antiviral agents will be approved for various combinations 
of interferon-free treatment options. However, in many countries 
approval and reimbursement of direct antiviral agents will be delayed. 
Also, PEGIFN/RBV therapy may be cost effective option to achieve 
an SVR in a subgroup of patients with beneficial genetic predictors of 
treatment response. Additionally, patients who have contraindications 
to these newer therapies will still need an interferon-based regimen, 
and thus the  IL28B gene  polymorphisms will still be important in 
predicting treatment response and prognosis.
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